Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders

Author(s): Alessio Cardinale, Daniela Merlo, Paolo Giunchedi, Silvia Biocca

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 38 , 2014

Become EABM
Become Reviewer
Call for Editor


Many neurodegenerative diseases, referred to as misfolding diseases, are characterized by the formation and accumulation of pathological extracellular and intracellular misfolded aggregates. Ageing is considered the major risk factor for neurodegenerative disorders and, due to increase of mean lifespan, the clinical relevance is growing dramatically with a urgent need to find new effective therapeutic approaches. The intracellular antibody technology is a gene-based strategy which exploits the specificity of recombinant antibodies to neutralize or modify the function of intracellular and extracellular target antigens. Intrabodies can potentially recognize all the pathological conformers of a misfolding-prone protein, and therefore they are emerging as therapeutic agents for the treatment of misfolding diseases as well as molecular tools for the understanding of their pathogenesis.

Here we focus on the application of intrabodies against two major age-related neurodegenerative disorders, Alzheimer’s disease (AD) and Parkinson’s disease (PD) and the description of in vivo gene delivery systems available for their potential entering in the clinical setting.

Keywords: Neurodegenerative diseases, intrabody, scFv, nanotechnology, gene delivery.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 25 September, 2014
Page: [6028 - 6036]
Pages: 9
DOI: 10.2174/1381612820666140314121444
Price: $65

Article Metrics

PDF: 23